Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience

Thomas Reynaud, MD1, Aurélie Bertaut, MD, PhD2, Walid Farah, MD3, David Thibouw, MD1, Gilles Crehange, MD, PhD1, Gilles Truc, MD1, and Noémie Vulquin, MD1

Abstract
Background and Purpose: The aim of this study was to investigate the survival outcomes and safety of hypofractioned stereotactic radiotherapy as a salvage treatment for recurrent high-grade glioma. Patients and Methods: Between March 2012 and March 2017, 32 consecutive patients (12 women, 20 men) treated in a single center were retrospectively included in this study. Grade III gliomas were diagnosed in 14 patients and grade IV in 18 patients. Thirty-four lesions were treated with hypofractionated stereotactic radiotherapy on a linear accelerator. Hypofractionated stereotactic radiotherapy delivered a median dose of 30 Gy (27-30) in 6 fractions (3-6) of 5 Gy (5-9). The treatment plans were normalized to 100% at the isocenter and prescribed to the 80% isodose line. Clinical outcomes and prognostic factors were analyzed. Results: Median follow-up was 20.9 months. Median overall survival following hypofractionated stereotactic radiotherapy was 15.6 months (median overall survival for patients with glioblastoma and grade III glioma was 8.2 and 19.5 months, respectively; \(P = .0496\)) and progression-free survival was 3.7 months (median progression-free survival for patients with glioblastoma and grade III glioma was 3.6 and 4.5 months, respectively; \(P = .2424\)). In multivariate analysis, tumor grade III (\(P = .0027\)), an Eastern Cooperative Oncology Group status <2 at the time of reirradiation (\(P = .0023\)), and a mean dose >35 Gy (\(P = .0055\)) significantly improved overall survival. A maximum reirradiation dose above 38 Gy (\(P = .0179\)) was significantly associated with longer progression-free survival. Conclusion: Hypofractionated stereotactic radiotherapy is well tolerated and offers an effective salvage option for the treatment of recurrent high-grade gliomas with encouraging overall survival. Our results suggest that the dose distribution had an impact on survival.

Keywords
recurrence, high-grade glioma, hypofractionated, stereotactic radiotherapy, salvage

Abbreviations
BED, biologically effective dose; CI, confidence interval; CTV, clinical target volume; CT, computed tomography; Dmax, maximum dose; Dmean, mean dose; Dmin, minimum dose; GBM, glioblastoma; ECOG, Eastern Cooperative Oncology Group; HFSRT, hypofractionated stereotactic radiotherapy; HGG, high-grade glioma; MRI, magnetic resonance imaging; PCV, lomustine, procarbazine and vincristine; PFS, progression-free survival; PTV, planning target volume; OS, overall survival; TMZ, temozolomide.

Received: December 28, 2017; Revised: June 15, 2018; Accepted: July 25, 2018.

Introduction
High-grade gliomas (HGGs) are the most frequent brain tumors in adults, with an annual incidence of 6 cases per one hundred thousand worldwide.1

The main current recommendation for treatment is full microsurgical resection for all patients. If this is not feasible, a stereotactic biopsy should be carried out. After surgery,
patients should receive radiotherapy and chemotherapy based on histology and molecular analysis.2-6

Unfortunately, these malignant brain tumors are radiosensitive and chemoresistant and have a very poor prognosis. Also, the risk of relapse and progression is inevitable.2,7

The management of tumor recurrence is not standardized and may be difficult. It requires an individual evaluation based on age, performance status, histology, extent of the initial resection, type of response to initial therapy, time since diagnosis, and recurrence size.8,9

The treatment of HGG recurrences and progressions must be evaluated in multidisciplinary tumor board and a surgical treatment must be systematically discussed. The other possible treatments include radiotherapy, chemotherapy (temozolomide [TMZ]; fotemustine; lomustine, procarbazine, and vincristine [PCV], etc), targeted therapies (bevacizumab), or novel agents which are proposed in the framework of clinical trials.10

For the treatment of HGG recurrence by radiotherapy, many approaches have been studied, including brachytherapy, single-fraction radiosurgery, hypofractionated stereotactic radiotherapy (HFSRT), or conventional fractionated radiotherapy10-18; however, none of these treatments demonstrated significant improvement in a phase III study.

Nevertheless, stereotactic radiotherapy is an interesting approach because it is minimally invasive, ambulatory, short-lasting, and well tolerated.17 Several studies19-46 have reported the feasibility of HFSRT as it shows potential efficacy and acceptable toxicity for the treatment of recurrent HGGs.

The aim of this study was to evaluate the efficacy of and safety to HFSRT as a salvage treatment for patients suffering from HGG relapse in our cancer center and to compare these results with the literature.

Material and Methods

Between March 2012 and March 2017, 32 consecutive patients with recurrent HGG received HFSRT at the Department of Radiation Oncology of Georges-François Leclerc Cancer Center in Dijon, Burgundy, France.

Eligibility Criteria

The study was approved by our institutional review board. The study included patients with HGG diagnosed on the initial pathological analysis and patients who presented a transformation from a low-grade lesion into a high-grade lesion during follow-up (contrast-enhanced magnetic resonance imaging [MRI]). All patients underwent neurosurgery followed by fractionated brain irradiation with a standard dose (54 or 60 Gy) with or without chemotherapy. Tumor progression or recurrence was assessed by MRI scans during follow-up or when the neurological condition of patients deteriorated. The decision to treat the relapse with HFSRT was confirmed in a multidisciplinary neuro-oncology tumor board.

Treatment Planning

Computed tomography (CT) simulations with slice thickness of 1.25 mm were performed, using a LightSpeed RT16 Vision (GE Health Care, Milwaukee, Wisconsin). During the planning CT, patients were fitted with a thermoplastic mask system dedicated to stereotactic treatment to ensure immobilization and reproducibility. Patients were treated with a stereotactic approach, using intensity-modulated radiation therapy (5-7 static fields) or volumetric-modulated arc therapy (1-4 arcs) technology with a Varian linear accelerator (Varian Medical Systems, Palo Alto, California): Trilogy with SonArray patient positioning system and Bite-Block system. Since 2015, a NovalisTx with BrainLAB and Exatrac systems (BrainLAB, Munich, Germany) has been used.

The dose prescribed for reirradiation was based on the localization of prior radiation therapy, the site of the lesion, and its proximity to organs at risk or the recurrence volume.

A total dose of 30 Gy in 6 fractions with 2 or 3 fractions per week was delivered, corresponding to a biologically effective dose (BED) of 80 Gy \( \frac{a}{b} = 3 \) and 45 Gy \( \frac{a}{b} = 10 \). For a reirradiation in the initial planning target volume (PTV), a cumulative BED with the first course (60 Gy in 30 fractions) corresponded to 180 Gy \( \frac{a}{b} = 3 \) and 117 Gy \( \frac{a}{b} = 10 \). One patient, who had 2 lesions, was treated with 27 Gy in 3 fractions with 3 fractions per week on each lesion (BED = 108 Gy; \( \frac{a}{b} = 3 \)-51.3 Gy; \( \frac{a}{b} = 10 \) and a cumulative BED of 208 Gy \( \frac{a}{b} = 3 \) or 123.3 Gy \( \frac{a}{b} = 10 \)). The treatment plans were normalized to 100% at the isocenter and prescribed to the 80% isodose line. Treatment was planned using the fusion of CT and MRI images. The clinical target volume (CTV) corresponded to the gross target volume obtained using contrast-enhanced T1-weighted MRI, edema (T2 FLAIR) was not included in the CTV. This volume was expanded by margins of 2 or 3 mm to generate the PTV, except for one of the first patients treated with a 5 mm PTV. The medullary canal, brainstem, whole brain, normal brain (whole brain minus PTV minus cerebellum), anterior and posterior chambers of eyeballs, chiasma, optical nerves, and cochlea, defined as organ at risks, were delineated.

The Eclipse Treatment Planning System (version 11) was used with Analytical Anisotropic Algorithm model to plan dosimetry. A Patient-Specific Quality Assurance has been performed before start of treatment.

Concomitant Drugs

Most patients (31; 96.9%) were treated without chemotherapy. One (3.1%) patient received concomitant bevacizumab (10 mg/kg, every 2 weeks).

Follow-Up

Clinical and radiological data for follow-up were collected at the first medical consultation after HFSRT (for adjuvant chemotherapy or systematic follow-up), and after each medical
consultation with a radiological (MRI) evaluation and at each change of therapeutic line. This radiological evaluation has been performed every 3 months after reirradiation.

The primary endpoint of this study was survival. Overall survival (OS) was calculated from the end of the HFSRT. Progression-free survival (PFS) was calculated from the end of HFSRT until tumor progression or death (by any cause). Tumor progression was defined according to response assessment in neuro-oncology criteria. The secondary endpoint of this study was toxicity, which was classified according to the common terminology criteria for adverse events v 4.03.

**Statistical Analysis**

Categorical variables are presented as percentages and were compared using the $\chi^2$ or Fisher test. Continuous variables are described as means (with standard deviations) and medians (with ranges) and were compared using the Student or Wilcoxon test in case of non-normal distribution. The median survival time was estimated using the reverse Kaplan-Meier method. Survival probabilities were estimated using the Kaplan-Meier method and the log-rank test was used to compare survival curves. Hazard ratios and their 95% confidence interval for univariate and multivariate analysis of OS were estimated using a Cox proportional hazards regression model. Correlations between covariates were tested for eligible variables. To prevent collinearity, when 2 variables were significantly correlated, one variable was retained according to its clinical relevance or to the value of the likelihood ratio. Statistical analyses were performed using SAS 9.3 software. All tests were 2 sided, and $P$ values were considered significant when less than .05.

**Results**

**Patients**

The characteristics of 32 patients are resumed in Table 1. The median age at HGG diagnosis was 57.5 (29-76) years. There were 20 (62.5%) men and 12 (37.5%) women. At the moment of recurrence, all patients presented an HGG: 18 (56.25%) glioblastoma (GBM) and 14 (43.75%) grade III gliomas. According to the 2007 World Health Organization classification in force at the time of diagnosis, there were 60 Gy (54-60) in conventional fractionation; 2 patients (6.25%) received 54 Gy in 27 fractions and the other (93.75%) patients 60 Gy in 30 fractions. Six patients (18.75%) had radiotherapy alone and 26 (81.25%) received concomitant chemotherapy according to the Stupp protocol. 4 Patients had also received bevacizumab as part of a protocol.

**Primary Treatment**

All patients had undergone at least one neurosurgical intervention. At the initial diagnosis, gross total resection was performed in 6 patients (18.75%), subtotal resection was performed in 17 patients (53.13%), a stereotactic biopsy was done in 8 patients (25%), and the surgical status was unknown for 1 patient (3.1%). Three patients (9.38%) underwent a second surgery prior to the radiation therapy.

All of the patients received a full course of radiation therapy with a median dose of 60 Gy (54-60) in conventional fractionation; 2 patients (6.25%) received 54 Gy in 27 fractions and the other (93.75%) patients 60 Gy in 30 fractions. Six patients (18.75%) had radiotherapy alone and 26 (81.25%) received concomitant chemotherapy according to the Stupp protocol. 2 Four patients also had concomitant bevacizumab as part of a protocol.

Table 1. Patients and Initial Tumor Characteristics.

| Patients | N = 32 |
|----------|--------|
| Women | 12 (37.5%) |
| Men | 20 (62.5%) |
| Median age at HGG diagnosis | 57.5 (29.0-76.0) |
| Pathology | |
| Oligodendroglioma | 9 (28.1%) |
| Oligoastrocytoma | 2 (6.3%) |
| Astrocytoma | 3 (9.4%) |
| Glioblastoma | 18 (56.3%) |
| Methylation MGMT | |
| Yes | 7 (21.9%) |
| No | 6 (18.8%) |
| Unknown | 19 (59.4%) |
| Mutation IDH1 | |
| Yes | 1 (3.1%) |
| No | 5 (15.6%) |
| Unknown | 26 (81.3%) |
| lp19q codeletion | |
| No | 4 (12.5%) |
| Unknown | 28 (87.5%) |

| Treatment characteristics | |
| Extent of surgery | |
| Gross total resection | 6 (19.4%) |
| Subtotal resection | 17 (54.8%) |
| Stereotactic biopsy | 8 (25.8%) |
| Unknown | 1 (3.1%) |
| Salvage surgery prior to initial irradiation | |
| Subtotal resection | 2 (6.3%) |
| Unknown | 1 (3.1%) |
| No | 29 (90.6%) |
| Chemotherapy prior to initial irradiation | |
| Radiochemotherapy | |
| Radiotherapy alone | 6 (18.75%) |
| Radio chemotherapy | 26 (81.25%) |
| Dose | |
| 60 Gy/30 fr | 30 (93.75%) |
| 54 Gy/27 fr | 2 (6.25%) |
| Concomitant chemotherapy | |
| TMZ | 22 (68.7%) |
| TMZ + bevacizumab | 4 (15.4%) |
Disease Evolution

The median time between HGG diagnosis and the first recurrence or progression was 1.3 (0-8.4) years and time between the initial radiation therapy and the first recurrence was 1.2 (0.08-11.3) years. The median number of recurrences prior to the HFSRT was 2 (1-5), and 18 patients (56.25%) received 1 to 3 systemic salvage therapies with various agents such as PCV, TMZ, bevacizumab, fotemustine, and erlotinib.

Seven patients (21.88%) had salvage neurosurgery (4 with macroscopic resection and 3 with subtotal surgery), 1 patient (3.1%) had 2 surgeries: the first macroscopic and the second subtotal.

Recurrence at the Time of HFSRT

At the time of the HFSRT, the median age was 61.5 (33-77) years. Ten (31.3%), 14 (43.8%), and 8 (25%) patients had an Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2, respectively. The recursive partitioning analysis status was III for 7 (21.9%), IV for 12 (37.5%), V for 11 (34.4%), and VI for 2 (6.3%) patients.

The median time between the HGG diagnosis and HFSRT was 2 (0.6-13.4) years while the time between the primary radiotherapy and reirradiation was 1.9 (0.5-13.2) years.

Two patients (6.25%) presented bifocal recurrence at the time of the HFSRT. The characteristics of the 34 lesions treated with HFSRT are resumed in Table 2.

The majority of recurrences (23; 67.7%) were localized within the initial PTV, 2 (5.9%) were localized outside and 1 (2.9%) was on the periphery (defined as 1 cm on either side of the initial PTV boundaries). For 8 (23.5%), the relationship with the initial PTV was unknown (initial dosimetric data were lost when computer versions were updated).

HFSRT Characteristics

The median tumor volume was of 6.1 (0.1-42.2) cm³, the PTV was 15 (0.6-67.5) cm³, and the prescription volume (isodose line 80%) was 19.1 (1.4-66.6) cm³. The median maximum dose (Dmax) was 35.1 (31.5-37.5) Gy, respectively. For patients with grade III glioma, the median minimum dose (Dmin) and median mean dose (Dmean) were 38.7 (32.7-42.0), 29.1 (14.0-32.4), and 35.1 (31.5-37.5) Gy, respectively.

Most patients (24; 75%) were subsequently treated with various agents such as TMZ, bevacizumab, fotemustine, lomustine, PCV, erlotinib, afatinib, or C-MET inhibitor after the HFSRT and/or at the new recurrence.

At the time of analysis, no patients had undergone another surgery following the HFSRT.

Survival

The median follow-up was 20.9 (2.8-47.4) months. At the time of the analysis, 20 patients (62.5%) had died.

OS following HFSRT. Median OS calculated from the reirradiation was 15.6 (8.2-17.3) months. The survival rate at 6 and 12 months was 83.4% and 64.6%, respectively. Median OS for patients with GBM was 8.2 (5.7-17.3) months and that for patients with grade III glioma was 19.5 (12.6-24) months (Figure 1).

In univariate analysis, the initial irradiation technique, the initial T2 FLAIR volume, concomitant bevacizumab with the primary irradiation, reirradiation tumor volumes, and reirradiation mean dose were significant prognostic factors ($P < .05$) of OS (Table 3). In multivariate analysis, tumor grade III ($P = .0027$), a mean dose $>35$ Gy ($P = .0055$), and an ECOG status.
<2 at the time of reirradiation ($P = .0023$) significantly improved OS (Table 3).

**Progression-free survival.** The PFS after HFSRT was 3.7 (3-5.7) months overall: 3.6 (2.4-5.6) months for patients with GBM and 4.5 (2.9-8.9) months for patients with grade III glioma (Figure 2).

The median time to the first MRI evaluation after HFSRT was 3 (1-10) months.

**Toxicity**

Treatment was completed in all patients in the specified time. All patients were included in the analysis. One patient was lost to follow-up at the end of the HFSRT. Treatment was well tolerated, no acute toxicity >grade 2 was observed, and the neurological deteriorations correlated with neoplastic progression during the follow-up. Nevertheless, one patient presented homonymous hemianopsia during the HFSRT, but this resolved during the follow-up. Ten patients (31.25%) had suspected radionecrosis. If in doubt between radionecrosis or progression, a new MRI at 2 months or a multimodal MRI has been proposed. In 6 patients, this suspicion corresponded to tumor progression. For the other patients, radionecrosis was suggested on multimodal MRI. These patients had asymptomatic radionecrosis at the time of diagnosis.

**Discussion**

The standard of care for patients with recurrent GBM or grade III glioma has not yet been clearly defined, and many approaches are available for salvage strategies, including surgery, reirradiation, or systemic agents.\(^{10-18}\)

In the current study, we evaluated the feasibility of HFSRT as a salvage treatment for HGG. Our patients were long survivors, as the median time between HGG diagnosis and the first relapse and the time between the initial radiotherapy and HFSRT were 1.3 and 1.9 years, respectively. This can be explained by the large proportion of patients with grade III glioma (43.75%). In addition, 7 patients presented a transformation from low-grade glioma to HGG with a slow disease evolution. Furthermore, most patients had experienced several relapses between the initial radiation therapy and the HFSRT (median number: 2), and management was often multimodal with different treatments (new surgery, chemotherapy).

Fogh et al\(^35\) reported that patients with early relapse from initial irradiation (<6 months) had a more unfavorable

| Table 3. Univariate and Multivariate Analysis: Prognostic Factors for OS. | HR | 95% CI | P Value |
|---|---|---|---|
| Univariate analysis for OS following HFSRT | | | |
| Initial irradiation technique: IMRT vs 3D | 0.227 | 0.056-0.926 | .0388 |
| Initial T2 FLAIR volume: >100 cm\(^3\) vs ≤100 cm\(^3\) | 4.147 | 1.085-15.856 | .0376 |
| Initial irradiation with concomitant bevacizumab: yes vs no | 4.853 | 1.505-15.649 | .0082 |
| HSRT GTV volume: >6 vs ≤6 cm\(^3\) | 5.185 | 1.691-15.900 | .0400 |
| HSRT PTV volume: >15 vs ≤15 cm\(^3\) | 3.281 | 1.169-9.208 | .0240 |
| Prescription volume (isodose line 80%): >19 vs ≤19 cm\(^3\) | 3.281 | 1.169-9.208 | .0240 |
| Multivariate analysis for OS following HFSRT | | | |
| Tumor grade: grade IV vs grade III | 6.234 | 1.887-20.591 | .0027 |
| Stereotactic mean dose: >35 Gy vs ≤35 Gy | 0.219 | 0.075-0.639 | .0055 |
| ECOG status: 2 vs 0-1 | 8.115 | 2.108-31.240 | .0023 |

| Table 4. Univariate and Multivariate Analysis: Prognostic Factors for PFS. | HR | 95% CI | P Value |
|---|---|---|---|
| Univariate analysis for PFS | | | |
| Maximum dose: >38 Gy vs ≤38 Gy | 0.74 | 0.146-0.958 | .0405 |
| Multivariate analysis for PFS | | | |
| Stereotactic maximum dose: >38 Gy vs ≤38 Gy | 0.317 | 0.122-0.820 | .0179 |

Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; HR, hazard ratio; HFSRT, hypofractionated stereotactic radiotherapy; IMRT, intensity-modulated radiation therapy; PTV, planning target volume; OS, overall survival.

**Figure 2.** Kaplan-Meier PFS after HFSRT for patients with GBM and grade III glioma. PFS indicates progression-free survival; HFSRT, hypofractionated stereotactic radiotherapy; GBM, glioblastoma.
In the literature, many authors have studied hypofractionated or moderately fractionated stereotactic radiotherapy delivered with a linear accelerator for the management of HGG recurrence and also concluded that HFSRT reirradiation for HGG recurrence is feasible with minimal adverse effects, suggesting they should not qualify for salvage treatment. However, Laing et al. reported that a dose $\geq 40$ Gy was a major predictor of toxicity (especially major consumption of corticosteroids) in patients treated with doses of 20 to 50 Gy in 5 fractions (prescription: isodose $80\%$ or $90\%$), thus highlighting the small therapeutic windows.

Recently, Clarke et al. evaluated a dose-escalation strategy for the management of recurrent HGG treated with HFSRT in a phase I study. Their scheme was based on a previous study (Gutin et al.), which reported the feasibility of HFSRT with a scheme of 30 Gy in 5 fractions, prescribed to the 100\% isodose line. The dose-escalation study evaluated tolerance of 3 dose steps: $3 \times 9$ Gy, $3 \times 10$ Gy, and $3 \times 11$ Gy in combination with bevacizumab. The results attested the feasibility of the strategy at doses up to 33 Gy in 3 fractions.

In the literature, the reported OS is in the range of 6 (Selche et al.) to 17.7 months (Antoni et al.), and PFS ranged from 3 (Ogura et al.) to 12 months (Fokas et al., Antoni et al.). In our data, OS was 15.6 months; this good result could have been explicated by the high proportion (43.75\%) of patients treated for grade III glioma. Our results suggest that grade III glioma was a significant prognostic factor for longer OS; the specific OS for grade III glioma was 19.5 months versus 8.2 months for GBM. Indeed, these different pathologies have different courses and prognoses; survival was better in patients with grade III gliomas especially since these gliomas develop from low-grade gliomas.

Equally, a high proportion (71.9\%) of patients had gross or subtotal initial surgery, which may have had an impact on patient survival.

Although our patient population was in keeping with populations in the literature with respect to the characteristics of patients, tumor recurrences, and the stereotactic technique, PFS in our study was low.

The first progressions suspected on MRI after HFSRT were inside the PTV for majority of patients. Niyazi et al. reported a similar recurrence pattern after fractionated reirradiation with bevacizumab in a study of 31 patients treated for recurrent HGG. Altogether, 61.3\% of progressions were in-field, and 38.7\% at the margin or ex-field. Similarly, Shapiro et al. used a reirradiation regimen of 30 Gy in 5 fractions with concomitant bevacizumab to treat 24 patients with HGG relapse and studied recurrence patterns: 52.4\% progressions were in-field, 38.8\% were marginal, and 38.8\% were outside the field.

Actually, it is quite challenging to interpret radiological evaluation imaging after stereotactic radiotherapy because it is difficult to distinguish between progression, pseudoprogression, and radionecrosis. Thus, the short PFS could be explained by an overestimation of progression and an underestimation of radionecrosis.
| Authors and Year | Number of Patients | Median Age | GBM/Grade III | Median KPS | Total Dose; Number of Fractions; Number of Fr per Week | PTV Margins (mm) | IDS | Median Time Between Initial Irradiation and HFSRT (Months) | Surgery Before HFSRT | Associated Chemotherapy | OS (Months) | PFS (Months) | Prognostic Factors | Complications |
|-----------------|-------------------|------------|---------------|-----------|-----------------------------------------------------|-----------------|-----|----------------------------------------------------------|-------------------|------------------------|-------------|-------------|-------------------|----------------|
| Laing et al 1993 | 22                | 34 (14-56) | 12/7         | 70        | 20-50; 5; daily 2 | 80-90 | 25 (1-93) | 20 | 6 | – | 9.8 | – | – | Neurological deterioration: 5 |
| Glass et al 1997 | 20                | 44 (6-73)  | 13/7         | 90        | 42; 6 | 7; 2 | – | 70 | 14 (2-122) | 8 | – | CDDP | 13.7 | 4.6 | – | Radionecrosis: 3 |
| Shepherd et al 1997 | 33              | 37 (19-55) | 03/6        | 80        | 20-50; 5 | 4-10, daily 2 | 80-90 | 24 (3-93) | 29 | – | – | 11 | – | – | Radionecrosis: 6 |
| Hudes et al 1999 | 22                | 52 (2-67)  | 19/1         | 80/0 | 24; 6 | 4; 1 | – | 80-90 | 32.7 (1.5-150) | 7.8 | – | Paclitaxel | 7 | – | – | Reoperation: 2 |
| Shepherd et al 1997 | 33              | 56 (2-82)  | 19/1         | 80/0 | 24; 6 | 4; 1 | – | 80-90 | 32.7 (1.5-150) | 7.8 | – | Paclitaxel | 7 | – | – | Reoperation: 11 |
| Voyer et al 2002 | 21                | 54 (1-72)  | 14/7         | 80/0 | 20-35; 4-6 | 5; – | 0-3 | 70-90 | 11.6 (4.5-33.7) | 11 | 21% | – | 6 | 4 | – | Radionecrosis: 7 |
| Shepherd et al 2005 | 19              | 50 (1-74)  | 9/10         | 90        | 30-40; 5-8 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 2 | – | 9.3 | 4.9 | – | Tumor grade |
| Gross et al 2005 | 44                | 33 (0-75)  | 33/11        | 75        | 25-60; 5-30 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 21% | – | 9.3 | 4.9 | – | Tumor grade |
| Wurm et al 2006 | 25                | 46 (1-66)  | 20/5         | 80        | 30-50; 5-6 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 21% | – | 9.3 | 4.9 | – | Tumor grade |
| Ernst-Steenken et al 2007 | 15          | 49 (31-69) | 11/4        | 80        | 35-7; 3-5 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 21% | – | 9.3 | 4.9 | – | Tumor grade |
| Schwer et al 2008 | 15                | 47 (2-65)  | 11/4         | 80        | 35-7; 3-5 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 21% | – | 9.3 | 4.9 | – | Tumor grade |
| Fokas et al 2009 | 25                | 53 (2-71)  | 53/0         | 90        | 35-7; 3-5 | 5; 3 | – | 100 | 11.6 (4.5-33.7) | 11 | 21% | – | 9.3 | 4.9 | – | Tumor grade |
| Patil et al 2009 | 10                | 44 (2-60)  | 10/0        | 80        | 36; 6 | 6; 2 | – | 90 | 51.1 (6.1-123.3) | 14.9 | 7 | – | 7.5 | – | – | Radiographic responders |
| Gutin et al 2009 | 25                | 56 (3-80)  | 20/5        | 80        | 30-6 | 5; 5 | 100 | 34 (2-62) | 15 | – | Bevacizumab | GBM: 12.5 | Grade III: 16.5 | GBM: 7.3 | Grade III: 7.5 | – | Reoperation: 3 |
| Henke et al 2009 | 31                | 50 (1-67)  | 29/2        | 90        | 20-25; 4-5 | 4-5; 3-10 | – | – | 18 | 15 | – | 10.2 | – | – | Younger age |
| Fogh et al 2010 | 147               | 53 (2-80)  | 105/42      | 90        | 35; 3-5 | 10; daily | – | 85-90 | 22 (0-6-104) | 8 | 84 | Various agents | GBM: 8 | Grade III: 11 | – | Shorter time between diagnosis and recurrence |
| Minniti et al 2013 | 54         | 52 (3-90)  | 38/16       | 80        | 30-6 | 5; daily | 3-5 | 90 | 9.7 (3.1-32.3) | 15.5 | 12 | TMZ | 6 | 12 | – | Neurological deterioration grade 3: 4 |
| Shapiro et al 2013 | 24       | 56 (0-80)  | 20/4        | 80        | 30-6 | 5; 2 | 5 | – | – | – | 2 | Bevacizumab | 32.1 (from diagnosis) | 7.5 | – | Radiographic response |
| Ogura et al 2013 | 30                | 52.5 (19-81) | 15/9 | 22.5-35; 4-5 | 5 | daily | 1-2 | 70-80 | 3.02 (0.36-1) | 24.8 | – | Various agents | 10.4 | – | – | Radiomicrosis grade 3: 2 |
| Cemmela et al 2013 | 15        | 51.5 (41-73) | 9/10 | 90 | 25; 5 | 5; daily | 3-5 | 70 | – | 10.8 | – | – | 9.5 | – | – | Neurological deterioration: 2 |
| Wuthrick et al 2014 | 11       | 51 (3-67)  | 8/3         | 30-42; 2-3-3.75 | 10-15, daily 0 | 85-90 | 16.75 (0.05-72.01) | 19.5 | – | Sorafenib | 11 | 5.8 | – | – |
| Miwa et al 2014 | 21                | 53.9 (22-76) | 21/0 | 80 | 25-35; 5-7 | 5; daily | 3 | 80-95 | – | 12 | – | TMZ | 6 | – | – | Reoperation: 2 |
| Dincoglan et al 2015 | 28     | 55.6 (3-76) | 26/0 | 80 | 25-35 | 5; daily | 3 | 85-95 | – | 11.2 | – | – | 10.3 | – | – | Reoperation: 2 |

(continued)
| Authors and Year | Number of Patients | Median Age | GBM/Grade III | Median KPS | Total Dose; Dose per Fraction (Gy) | Number of Fractions; Number of fr per Week | PTV Margins (mm) | IDS | Median Tumor Volume (cm³) | Median Time Between Initial Irradiation and HFSRT (Months) | Surgery Before HFSRT | Associated Chemotherapy | OS (Months) | PFS (Months) | Prognostic Factors | Complications |
|-----------------|--------------------|------------|---------------|------------|-----------------------------------|---------------------------------------------|------------------|-----|---------------------------|-----------------------------------------------|----------------|------------------------|----------------|--------------|-------------------|---------------|
| Minniti *et al* 2015 | 54                  | 54 (30-72) | 42/12         | 70         | 25; 5                              | 5; daily                                    | 1-2              | 90  | 12.4 (1.8-43.3)            | 14                             | –              | Bevacizumab or fotemustine | 11 Bevacizumab | 6 Bevacizumab | KPS Grade Bevacizumab | Radionecrosis 3 |
| Shi *et al* 2016 | 12                  | 46 (33-66) | 8/4           | 80         | 30-35; 3-3.5                        | 10; daily                                    | 5                | –   | 26.8 (2.7-143)             | –                              | –              | Panobinostat 10-20-30 mg | 7.8, 6.1, 16.1 | –            | –                 | Radionecrosis grade 3:1 |
| Antoni *et al* 2016 | 20                  | 55.7 (33.9-82.9) | 13/7       | –         | 18.7-37.5; 6.25                    | 3-6; 3                                      | –                | 0.91 | 9 (0.02-18.5)              | 18.3                           | –              | TMZ Bevacizumab | 17.7 | 12          | Bevacizumab High-dose radiation | –            |
| Clarke *et al* 2017 | 15                  | 63 (50-73) | 10/5          | 90         | 27-33; 9-11                         | 3; –                                        | 2.5              | –   | –                         | –                             | –              | Bevacizumab | 13   | 7          | –                 | Radionecrosis grade 3:1 |
| Present study     | 32                  | 61.5 (33-77) | 18/14        | 80         | 27-30; 5-9                         | 3-6; 2-3                                    | 2-5              | 6.1  | 6.1 (0.1-42.2)             | 22.8                           | 7              | –                      | 15.6 | 3.7        | ECOG status Tumor grade Dose | –            |

Abbreviations: CT, computed tomography; fr, fraction; GBM, glioblastoma; GTV, gross tumor volume; HFSRT, hypofractionated stereotactic radiotherapy; IDS, isodose surface; KPS, Karnofsky performance score; MGMT, O6-methylguanin-DNA-methyltransferase; MRI, magnetic resonance imaging; OS, overall survival; PFS, progression-free survival; PTV, planning target volume; RPA, recursive partitioning analysis of prognostic factors; SPECT, single-photon emission computed tomography; TMZ, temozolomide.
Furthermore, it would be interesting to evaluate the effect of cumulative BED and the time between irradiations on the occurrence of radionecrosis. However, due to the small number of events and the limited number of patients, a relevant statistical analysis is not feasible.

The limitations of this study were its retrospective design, selection bias, and of various treatment factors, including surgery and chemotherapy before and after HFSRT. In addition, molecular biology information was only available for a minority of patients and specific statistical analyses were not available. However, our data were similar to those in the literature especially for the sample size.

**Conclusion**

The HFSRT appears to be a feasible and effective salvage treatment option for recurrent grade III glioma or GBM, with OS of 15.6 months. Prognostic factors associated with longer OS were a good general state of health and grade III glioma. Dosimetric data suggested that the dose distribution had an impact on tumor control and indicate that a study with dose-escalation is warranted. These results need to be confirmed in a prospective study with a greater number of patients.

**Acknowledgments**

Philip Bastable for correcting the manuscript.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Thomas Reynaud, MD [http://orcid.org/0000-0002-4376-0697](http://orcid.org/0000-0002-4376-0697)

**References**

1. Weller M, van den Bent M, Tonn JC, et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. *Lancet Oncol.* 2017;18(6):e315-e329. doi:10.1016/S1470-2045(17)30194-8.

2. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 2005;352(10):987-996.

3. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol (Berl).* 2016;131(6):803-820. doi:10.1007/s00401-016-1545 -1.

4. van den Bent MJ, Brandes AA, Taphoorn MJB, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. *J Clin Oncol.* 2013;31(3):344-350. doi:10.1200/JCO.2012.43.2229.

5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. *J Clin Oncol.* 2013;31(3):337-343. doi:10.1200/JCO.2012.43.2674.

6. Bent MJVD, Erridge S, Vogelbaum MA, et al. Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: an Intergroup trial. *J Clin Oncol.* 2016;34(suppl; abstr LBA2000).

7. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE. 3. *Lancet Oncol.* 2008;9(1):29-38.

8. Easaw JC, Mason WP, Perry J, et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. *Curr Oncol.* 2011;18(3):126-136.

9. Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma— are we there yet? *Neuro Oncol.* 2013;15(1):4-27. doi:10.1093/neuonc/nos273.

10. Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. *Radiother Oncol.* 2011;98(1-14). doi:10.1016/j.radonc.2010.11.006.

11. Amelio D, Amichetti M. Radiation therapy for the treatment of recurrent glioblastoma: an overview. *Cancers.* 2012;4(4):257-280. doi:10.3390/cancers4010257.

12. Nieder C, Andratschke NH, Grosu AL. Re-irradiation for recurrent primary brain tumors. *Anticancer Res.* 2016;36(10):4985-4996. doi:10.21873/anticanceres.11067.

13. Dong Y, Fu C, Guan H, et al. Re-irradiation alternatives for recurrent high-grade glioma (review). *Oncol Lett.* 2016;12(4):2261-2270. doi:10.3892/ol.2016.4926.

14. Amichetti M, Amelio D. A review of the role of re-irradiation in recurrent high-grade glioma (HGG). *Cancers.* 2011;3(4):4061-4089. doi:10.3390/cancers3044061.

15. Seystahl K, Wick W, Wellers M. Therapeutic options in recurrent glioblastoma—and an update. *Crit Rev Oncol Hematol.* 2016;99:389-408. doi:10.1016/j.critrevonc.2016.01.018.

16. Ryu S, Buatti JM, Morris A, Kalkanis SN, Ryken TC, Olson JI. The role of radiotherapy in the management of progressive glioblastoma: a systematic review and evidence-based clinical practice guideline. *J Neurooncol.* 2014;118(3):489-499. doi:10.1007/s11060-013-1337-6.

17. Clavien J-B, Voisin J, Kehrl P, Noël G. Radiothérapie en conditions stéréotaxiques des gliomes de haut grade: une revue de la littérature [in French]. *Cancer Radiothérapie.* 2010;14(8):739-754. doi:10.1016/j.canrad.2010.03.021.

18. Romanelli P, Conti A, Pontoriero A, et al. Role of stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of recurrent glioblastoma multiforme. *Neurosurg Focus.* 2009;27(6):E8.

19. Laing RW, Warrington AP, Graham J, Britton J, Hines F, Brada M. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). *Radiother Oncol.* 1993;27(1):22-29.

20. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW. Fractionated stereotactic radiotherapy with cis-platinum
radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. *Am J Clin Oncol.* 1997;20(3):226-229.

21. Shepherd SF, Laing RW, Cosgrove VP, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. *Int J Radiat Oncol Biol Phys.* 1997;37(2):393-398.

22. Hudes RS, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. *Int J Radiat Oncol Biol Phys.* 1999;43(2):293-298.

23. Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. *Am J Clin Oncol.* 2000;23(2):155-159.

24. Selch MT, DeSalles AA, Solberg TD, et al. Hypofractionated stereotactic radiotherapy for recurrent malignant gliomas. *J Radiosurg.* 2000;3(1):3-12.

25. Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. *Am J Clin Oncol.* 2002;25(6):606-611.

26. Vordermark D, Kölbl O, Ruprecht K, Vince GH, Bratengeier K, Flentje M. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. *BMC Cancer.* 2005;5(1):55. doi:10.1186/1471-2407-5-55.

27. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. *Int J Radiol Oncol.* 2005;63(2):511-519. doi:10.1016/j.ijrobp.2005.01.056.

28. Wurm RE, Kuczer DA, Schlenker L, et al. Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. *Int J Radiat Oncol.* 2006;66(4):S26-S32. doi:10.1016/j.ijrobp.2006.04.062.

29. Ernst-Steeken A, Ganslandt O, Lambrecht U, Sauer R, Grabenbauer G. Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma. *J Neurooncol.* 2007;81(3):287-294. doi:10.1007/s11060-006-9231-0.

30. Schwer AL, Damek DM, Kavanagh BD, et al. A Phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. *Int J Radiat Oncol.* 2008;70(4):993-1001. doi:10.1016/j.ijrobp.2007.07.2382.

31. Fokas E, Wacker U, Gross MW, Henzel M, Encheva E, Engelhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? *Strahlenther Onkol.* 2009;185(4):235-240. doi:10.1007/s00066-009-1753-x.

32. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. *J Neurooncol.* 2009;92(2):185-191. doi:10.1007/s11060-008-9752-9.

33. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. *Int J Radiat Oncol.* 2009;75(1):156-163. doi:10.1016/j.ijrobp.2008.10.043.

34. Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. *Strahlenther Onkol.* 2009;185(2):113-119. doi:10.1007/s00066-009-1969-9.

35. Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. *J Clin Oncol.* 2010;28(18):3048-3053. doi:10.1200/JCO.2009.25.6941.

36. Minniti G, Scaringi C, De Sanctis V, et al. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas. *J Neurooncol.* 2013;111(2):187-194. doi:10.1007/s11060-012-0999-9.

37. Shapiro LQ, Beal K, Goenka A, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. *Int J Radiat Oncol.* 2013;85(3):636-642. doi:10.1016/j.ijrobp.2012.05.031.

38. Ogura K, Mizowaki T, Arakawa Y, Sakanaka K, Miyamoto S, Hiraoka M. Efficacy of salvage stereotactic radiotherapy for recurrent glioma: impact of tumor morphology and method of target delineation on local control. *Cancer Med.* 2013;2(6):942-949. doi:10.1002/cam4.154.

39. Ciammella P, Podgornii A, Galeandro M, et al. Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience. *Radiat Oncol.* 2013;8(1):222.

40. Wuthrick EJ, Curran WJ, Camphausen K, et al. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. *Int J Radiat Oncol.* 2014;90(2):369-375. doi:10.1016/j.ijrobp.2014.05.034.

41. Miwa K, Matsuo M, Ogawa S, et al. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy. *Radiat Oncol.* 2014;9(1):181.

42. Dincoglan F, Beyzadeoglu M, Sager O, et al. Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. *Cancer Med.* 2015;4(2):179-184. doi:10.5301/tj.5000236.

43. Minniti G, Agolli L, Falco T, et al. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas. *J Neurooncol.* 2015;122(3):559-566. doi:10.1007/s11060-015-1745-x.

44. Shi W, Palmer JD, Werner-Wasik M, et al. Phase I trial of pono- binostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas. *J Neurooncol.* 2016;127(3):535-539. doi:10.1007/s11060-016-2059-3.

45. Antoni D, Jastaniah Z, Haoming QC, et al. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. *Cancer/Radiothérapie.* 2016;20(4):282-291. doi:10.1016/j.canrad.2016.03.006.

46. Clarke J, Neil E, Terziev R, et al. Multicenter phase I dose escalation study of hypofractionated stereotactic radiotherapy with
bevacizumab for recurrent glioblastoma and anaplastic astrocytoma. *Int J Radiat Oncol*. 2017;99(4):797-804. doi:10.1016/j.ijrobp.2017.06.2466.

47. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 1994;30(2):146-149.

48. Hervey-Jumper SL, Berger MS. Maximizing safe resection of low- and high-grade glioma. *J Neurooncol*. 2016;130(2):269-282. doi:10.1007/s11060-016-2110-4.

49. Niyazi M, Jansen NL, Rottler M, Ganswindt U, Belka C. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. *Radiat Oncol*. 2014;9(1). doi:10.1186/s13014-014-0299-y.